Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
Markus CornbergAdriana AhumadaAlessio AghemoMassimo AndreoniAbhi BhagatIsabel ButrymowiczMichal CarmielGabriel ChodickBrian ConwayYanna SongAntonio GasbarriniDietrich HüppeFrancisco Jorquera PlazaPietro LamperticoMaria Luisa Manzano AlonsoLindsay MylesMarcello PersicoAlnoor RamjiChristoph SarrazinErica VillaClara WeilJuan Isidro Uriz Otanonull nullPublished in: Advances in therapy (2022)
In this real-world cohort, 8 weeks of G/P therapy was well tolerated in TN patients with CC. SVR12 rates were similar to clinical trials, supporting 8-week treatment in TN patients with CC, including those with signs of advanced liver disease and GT3 infection.